Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099843 | 0.80 | ADRB2 (0.53) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| SCHEMBL4738429 | 0.76 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL8879323 | 0.72 | ADRB2 (0.61) | ADRB2ABCB11ADRB1DRD2PDE4A | |
| SCHEMBL14104153 | 0.72 | ADRB2 (0.61) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| SCHEMBL9522342 | 0.72 | ADRB2 (0.72) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| SCHEMBL4753827 | 0.71 | ADRB2 (0.55) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| SCHEMBL14100066 | 0.71 | ADRB2 (0.60) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL8882013 | 0.71 | ADRB2 (0.71) | ADRB2ABCB11ADRB1DRD2ADRA1D | |
| SCHEMBL14077127 | 0.70 | ADRB2 (0.56) | ADRB2ABCB11ADRB1DRD2PDE4A | |
| SCHEMBL9520760 | 0.69 | ADRB2 (0.66) | ADRB2ABCB11ADRB1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008096129-A1 | NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |